Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board...
February 18 2021 - 8:30AM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or
"Company"), a clinical stage biotechnology company developing
cellular therapies for chronic aging-related and life-threatening
conditions, today announced the appointments of Douglas Losordo,
M.D., Erin Borger, and Cathy Ross to the Company’s Board of
Directors.
Douglas Losordo, MDDr. Losordo
has worked in the biotech industry for over twenty years, most
recently serving as Executive Vice President, Head of Research and
Development and Chief Medical Officer of KBP Biosciences Inc. Dr.
Losordo was previously the Executive Vice President, Global Head of
Research and Development, Chief Medical Officer of Caladrius
Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical
company dedicated to the development of cellular therapies designed
to reverse chronic disease, from August 2013 until November 2020.
Dr. Losordo has extensive knowledge of clinical, regulatory,
manufacturing, supply chain and commercial factors unique to
cellular therapy technologies as a result of his prior industry
experience. Dr. Losordo’s also previously served as a Professor of
Medicine at NYU Langone Medical Center and Northwestern
University’s Feinberg School of Medicine. He received his MD from
the University of Vermont College of Medicine, and his B.A. in
Zoology from the University of Vermont.
Erin BorgerMr. Borger is a
Managing Director in Wealth Management at UBS Financial Services
Inc., where he has worked since 2008. Throughout the years Mr.
Borger has also served as a member on a number of medical and
non-medical boards and committees, such as the Alzheimer’s
Association South Florida, Cystic Fibrosis Foundation, Palisades
Medical Center and the University of Miami, Miller School of
Medicine, to name a few. Additionally, Mr. Borger has spent a
number of years helping to support non-profit organizations with a
focus in the medical field through various research and financial
support. Mr. Borger received his B.A. in Sociology from Wofford
College, and also holds a number of securities licenses from the
Financial Industry Regulatory Authority.
Cathy RossMs. Ross is a senior
finance executive with over 30 years of experience. Since 2016, she
has been a member of the Board of Directors and Chair of the Audit
Committee of Fraud.Net, Inc., a privately held company that
operates a real-time fraud detection and analytics platform. From
2006 to 2012, she was the Chief Financial Officer, President, and a
member of the Board of Directors of MotherNature.com, a privately
held online retailer and information source for vitamins,
supplements, minerals and healthy products. In her role as Chief
Financial Officer of MotherNature.com, she managed all aspects of
accounting, budgeting and financial reporting. Prior to that, she
served as Managing Director, Private Equity of Oasis Capital
Partners, Vice President, Investment Banking and Public Offerings
of Commonwealth Associates, Product Development and Marketing
Manager of Ocwen Financial Corporation, and a Senior Credit Analyst
for Chase Manhattan Bank. Ms. Ross earned a Bachelor of Arts
Degree, Economics from Brown University in 1989.
The appointments of the new directors took
effect in connection with the Company’s recent initial public
offering and listing on the Nasdaq.
Geoff Green, CEO of Longeveron, stated, “We are
delighted to announce the appointments of such prominent industry
leaders to our board. Each is highly accomplished in their
respective fields and are valuable additions as we begin life as a
public company, and continue to make progress toward the goal of
developing cell therapies for aging-related chronic disease and
life-threatening conditions.”
About Longeveron
Longeveron is a clinical stage biotechnology
company developing cellular therapies for specific aging-related
and life-threatening conditions. The Company’s lead investigational
product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”),
which is derived from culture-expanded medicinal signaling cells
(MSCs) that are sourced from bone marrow of young, healthy adult
donors. Longeveron believes that by using the same cells that
promote tissue repair, organ maintenance, and immune system
function, it can develop safe and effective therapies for some of
the most difficult disorders associated with the aging process and
other medical disorders. Longeveron is currently sponsoring Phase 1
and 2 clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that
are not historical facts are forward-looking statements that
reflect management's current expectations, assumptions, and
estimates of future performance and economic conditions, and
involve risks and uncertainties that could cause actual results to
differ materially from those anticipated by the statements made
herein. Forward-looking statements are generally identifiable by
the use of forward-looking terminology such as "believe,"
"expects," "may," "looks to," "will," "should," "plan," "intend,"
"on condition," "target," "see," "potential," "estimates,"
"preliminary," or "anticipates" or the negative thereof or
comparable terminology, or by discussion of strategy or goals or
other future events, circumstances, or effects. Moreover,
forward-looking statements in this release include, but are not
limited to, statements about the ability of our clinical trials to
demonstrate safety and efficacy of our product candidates, and
other positive results; the timing and focus of our ongoing and
future preclinical studies and clinical trials; the size of the
market opportunity for our product candidates, the beneficial
characteristics, safety, efficacy and therapeutic effects of our
product candidates; our ability to obtain and maintain regulatory
approval of our product candidates, our plans and ability to obtain
or protect intellectual property rights, including extensions of
existing patent terms where available and our ability to avoid
infringing the intellectual property rights of others. Further
information relating to factors that may impact the Company's
results and forward-looking statements are disclosed in the
Company's filings with the SEC. The forward-looking statements
contained in this press release are made as of the date of this
press release, and the Company disclaims any intention or
obligation, other than imposed by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:Crescendo
Communications, LLCTel: 212-671-1020Email:
lgvn@crescendo-ir.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024